Clinical Trial Update: A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing ibrutinib versus lenalidomide in combination with MRE-chemotherapy for adult patients with recurrent or refractory primary central nervo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL) | Phase 2 | Status: UNKNOWN